Cargando…
P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430971/ http://dx.doi.org/10.1097/01.HS9.0000971304.81687.8d |
| _version_ | 1785091087528886272 |
|---|---|
| author | Shotton, Rohan Tivey, Ann Eyre, Toby A. Lewis, David Allchin, Rebecca Walter, Harriet Miall, Fiona Zhao, Rui Santarsieri, Anna Mcculloch, Rory Bishton, Mark Willimott, Victoria Fowler, Nicole Bedford, Claudia Goddard, Jack Protheroe, Samuel Prahladan, Mahesh Reeve, Miriam Paneesha, Shankara Marr, Helen Wilson, Jamie Ediriwickrema, Kushani Knott, Chloe Wrench, David Talbot, Georgina Linton, Kim |
| author_facet | Shotton, Rohan Tivey, Ann Eyre, Toby A. Lewis, David Allchin, Rebecca Walter, Harriet Miall, Fiona Zhao, Rui Santarsieri, Anna Mcculloch, Rory Bishton, Mark Willimott, Victoria Fowler, Nicole Bedford, Claudia Goddard, Jack Protheroe, Samuel Prahladan, Mahesh Reeve, Miriam Paneesha, Shankara Marr, Helen Wilson, Jamie Ediriwickrema, Kushani Knott, Chloe Wrench, David Talbot, Georgina Linton, Kim |
| author_sort | Shotton, Rohan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430971 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104309712023-08-17 P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY Shotton, Rohan Tivey, Ann Eyre, Toby A. Lewis, David Allchin, Rebecca Walter, Harriet Miall, Fiona Zhao, Rui Santarsieri, Anna Mcculloch, Rory Bishton, Mark Willimott, Victoria Fowler, Nicole Bedford, Claudia Goddard, Jack Protheroe, Samuel Prahladan, Mahesh Reeve, Miriam Paneesha, Shankara Marr, Helen Wilson, Jamie Ediriwickrema, Kushani Knott, Chloe Wrench, David Talbot, Georgina Linton, Kim Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430971/ http://dx.doi.org/10.1097/01.HS9.0000971304.81687.8d Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Shotton, Rohan Tivey, Ann Eyre, Toby A. Lewis, David Allchin, Rebecca Walter, Harriet Miall, Fiona Zhao, Rui Santarsieri, Anna Mcculloch, Rory Bishton, Mark Willimott, Victoria Fowler, Nicole Bedford, Claudia Goddard, Jack Protheroe, Samuel Prahladan, Mahesh Reeve, Miriam Paneesha, Shankara Marr, Helen Wilson, Jamie Ediriwickrema, Kushani Knott, Chloe Wrench, David Talbot, Georgina Linton, Kim P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY |
| title | P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY |
| title_full | P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY |
| title_fullStr | P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY |
| title_full_unstemmed | P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY |
| title_short | P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY |
| title_sort | p1102: ibrutinib and rituximab as first line therapy for mantle cell lymphoma: updated outcomes from a multicentre, real-world uk study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430971/ http://dx.doi.org/10.1097/01.HS9.0000971304.81687.8d |
| work_keys_str_mv | AT shottonrohan p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT tiveyann p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT eyretobya p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT lewisdavid p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT allchinrebecca p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT walterharriet p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT miallfiona p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT zhaorui p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT santarsierianna p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT mccullochrory p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT bishtonmark p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT willimottvictoria p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT fowlernicole p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT bedfordclaudia p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT goddardjack p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT protheroesamuel p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT prahladanmahesh p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT reevemiriam p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT paneeshashankara p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT marrhelen p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT wilsonjamie p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT ediriwickremakushani p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT knottchloe p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT wrenchdavid p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT talbotgeorgina p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy AT lintonkim p1102ibrutinibandrituximabasfirstlinetherapyformantlecelllymphomaupdatedoutcomesfromamulticentrerealworldukstudy |